MedPath

COMPASS Pathways

COMPASS Pathways logo
๐Ÿ‡ฌ๐Ÿ‡งUnited Kingdom
Ownership
Public
Established
2016-06-13
Employees
186
Market Cap
-
Website
http://www.compasspathways.com
Introduction

Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

Phase 2
Recruiting
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2023-02-17
Last Posted Date
2024-04-10
Lead Sponsor
COMPASS Pathways
Target Recruit Count
102
Registration Number
NCT05733546
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Kadima Neuropsychiatry Institute, La Jolla, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Clinical Neuroscience Solutions Inc, Jacksonville, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Sunstone Therapies, Rockville, Maryland, United States

and more 2 locations

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Phase 3
Recruiting
Conditions
Treatment Resistant Depression
Interventions
First Posted Date
2023-02-03
Last Posted Date
2025-06-12
Lead Sponsor
COMPASS Pathways
Target Recruit Count
568
Registration Number
NCT05711940
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Clinical Innovations, Inc., Bellflower, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Catalina Research Institute, LLC, Montclair, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

CITrials, Riverside, California, United States

and more 92 locations

Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Phase 3
Active, not recruiting
Conditions
Treatment Resistant Depression
Interventions
First Posted Date
2022-11-22
Last Posted Date
2025-05-09
Lead Sponsor
COMPASS Pathways
Target Recruit Count
255
Registration Number
NCT05624268
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Arizona College of Medicine - Tuscon, Tucson, Arizona, United States

๐Ÿ‡บ๐Ÿ‡ธ

ProScience Research Group, Culver City, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Collaborative Neuroscience Network, LLC, Garden Grove, California, United States

and more 37 locations

Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study

Phase 2
Completed
Conditions
Anorexia Nervosa
Interventions
First Posted Date
2022-08-01
Last Posted Date
2024-12-04
Lead Sponsor
COMPASS Pathways
Target Recruit Count
32
Registration Number
NCT05481736
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Altman Clinical and Translational Research Institute, San Diego, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Sheppard Pratt Health System, Baltimore, Maryland, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dell Medical School, Austin, Texas, United States

and more 2 locations

The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

Phase 2
Completed
Conditions
Post Traumatic Stress Disorder
Interventions
First Posted Date
2022-04-05
Last Posted Date
2025-06-13
Lead Sponsor
COMPASS Pathways
Target Recruit Count
22
Registration Number
NCT05312151
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Sunstone Therapies, Rockville, Maryland, United States

๐Ÿ‡บ๐Ÿ‡ธ

Icahn School of Medicine at Mount Sinai, New York, New York, United States

๐Ÿ‡ฌ๐Ÿ‡ง

Kings College London, Institute of Psychiatry, Psychology and Neurology, London, United Kingdom

The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression

Phase 2
Completed
Conditions
Treatment Resistant Depression
Interventions
First Posted Date
2021-02-05
Last Posted Date
2023-11-09
Lead Sponsor
COMPASS Pathways
Target Recruit Count
19
Registration Number
NCT04739865
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Kadima Neuropsychiatry Institute, La Jolla, California, United States

๐Ÿ‡ฎ๐Ÿ‡ช

Sheaf House, Tallaght Hospital, Dublin, Ireland

Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)

Completed
Conditions
Treatment Resistant Depression
First Posted Date
2020-08-20
Last Posted Date
2022-09-22
Lead Sponsor
COMPASS Pathways
Target Recruit Count
66
Registration Number
NCT04519957
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Kadima Neuropsychiatry Institute, La Jolla, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Altman Clinical and Translational Research Institute, University of California, San Diego, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Mood and Anxiety Disorders Program Emory University School of Medicine, Atlanta, Georgia, United States

and more 5 locations

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

Phase 2
Completed
Conditions
Treatment Resistant Depression
Interventions
First Posted Date
2018-12-13
Last Posted Date
2023-04-24
Lead Sponsor
COMPASS Pathways
Target Recruit Count
233
Registration Number
NCT03775200
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Kadima Neuropsychiatry Institute, La Jolla, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Altman Clinical and Translational Research Institute, University of California, San Diego, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Stanford Department of Psychiatry, Stanford, California, United States

and more 22 locations
ยฉ Copyright 2025. All Rights Reserved by MedPath